Summary basis of decision (SBD) for PrMOZOBIL™

Health Canada’s Summary Basis of Decision (SBD) documents outline the scientific and regulatory considerations that factor into Health Canada regulatory decisions related to drugs and medical devices. Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Read the full document here.